Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Study of ZN-c3 as a Single Agent in Subjects With Solid Tumors

Next Previous
Trial Profile

A Phase 1 Study of ZN-c3 as a Single Agent in Subjects With Solid Tumors

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 04 Feb 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Azenosertib (Primary) ; Pembrolizumab; Talazoparib
  • Indications Carcinoma; Solid tumours; Uterine cancer
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
  • Sponsors K-Group Beta; Zentalis Pharmaceuticals

Most Recent Events

  • 29 Jan 2025 Results published in the Zentalis Pharmaceuticals media release.
  • 16 Sep 2024 According to Zentalis Pharmaceuticals media release, company announced that the U.S. Food and Drug Administration (FDA) has lifted the partial clinical hold on studies of azenosertib.The FDA has cleared the Company to resume enrollment in all ongoing azenosertib clinical studies with no changes in the clinical development plan.
  • 18 Jun 2024 According to Zentalis Pharmaceuticals media release, The company remains on track to present results from the ZN-c3-001 and Phase 1/2 ZN-c3-006 (MAMMOTH) studies later this year.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top